ADT1102-Bococizumab Biosimilar-Anti-PCSK9/NARC1/PC9 mAb-Research Grade
- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1102 |
Product Name |
ADT1102-Bococizumab Biosimilar-Anti-PCSK9/NARC1/PC9 mAb-Research Grade |
Clonity |
Monoclonal |
|
Alternate Names anti-mouse PCSK9 antibody, anti-PCSK9 antibody, anti PCSK9 antibody, recombinant PCSK9, PCSK9 antibody, anti-PCSK9 monoclonal antibody, PCSK9 antibodies, PCSK9 recombinant antibody, PCSK9 blocking antibody, NARC1 recombinant antibody, NARC1 blocking antibody, PC9 recombinant antibody, PC9 blocking antibody |
|
Alias |
PF-04950615, RN-316 |
Host |
CHO Cells |
Species |
Human |
Target |
PCSK9/NARC1/PC9 |
Gene ID |
351 |
Isotype |
IgG2 Kappa |
Size |
100ug, 1mg, 5mg |
Research Area |
Cardiovascular |
CAS Number |
1407495-02-6 |
Product Description |
Bococizumab (USAN, development code RN316) is a drug that was in development by Pfizer targeting PCSK9 to reduce LDL cholesterol. Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders." |
Application |
FC, IP, ELISA, Neut, Functional assay |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
Reference |
1. Cai J, et al. Immun Inflamm Dis, 2023 May. PMID 37249282
2. Meng FH, et al. Arterioscler Thromb Vasc Biol, 2023 Jul. PMID 37165876
3. Menichelli D, et al. Kardiol Pol, 2023. PMID 36929300
|